Rockefeller Capital Management
PRVB

Rockefeller Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Rockefeller Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,000
Closed -$31K – 4180
2022
Q4 		$31K Hold
3,000
– – ﹤0.01% 2626
2022
Q3 		$13K Hold
3,000
– – ﹤0.01% 2990
2022
Q2 		$12K Hold
3,000
– – ﹤0.01% 3044
2022
Q1 		$21K Hold
3,000
– – ﹤0.01% 2709
2021
Q4 		$16K Hold
3,000
– – ﹤0.01% 2769
2021
Q3 		$19K Hold
3,000
– – ﹤0.01% 2620
2021
Q2 		$25K Sell
3,000
-26,700
-90% -$215K ﹤0.01% 2396
2021
Q1 		$311K Buy
+29,700
New +$418K ﹤0.01% 1189

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Rockefeller Capital Management's PRVB Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 3,000 shares — an estimated $31K sold.

Rockefeller Capital Management first reported a position in PRVB in Q1 2021 and held it in 8 quarters. The position peaked at $311K in Q1 2021. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 3,000 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $31K.
  • Rockefeller Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • Rockefeller Capital Management's Provention Bio, Inc. Common Stock position peaked at $311K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.